Pre-exposure Prophylaxis
Active Resources: 30
Slide Sets
-
9/28/2020
-
9/28/2020
-
7/31/2020
-
6/2/2020
-
5/28/2020
-
4/10/2020
-
3/30/2020 (reviewed: 9/24/2020)
-
11/1/2017
Online Training
-
9/14/2020
-
12/4/2019
Toolkits
-
6/3/2020 (reviewed: 6/5/2020)
-
6/10/2019
Webinar Recordings
-
6/2/2020
-
5/21/2020 (reviewed: 6/19/2020)
-
4/29/2020 (reviewed: 6/19/2020)
-
9/20/2019
Online and Self-Paced Learning
-
5/22/2020
-
2/5/2019 (reviewed: 9/19/2020)
-
11/2/2016
Charts, Tables & Posters
-
3/4/2020
Videos
-
8/15/2019
Pocket Guides
-
2/25/2019 (reviewed: 10/31/2019)
Articles & Bibliographies
-
2/15/2019 (reviewed: 10/7/2019)
Clinical Reference Tools
-
12/11/2018
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
11/1/2018
-
10/1/2017
-
4/18/2016 (reviewed: 5/23/2018)
-
8/10/2012
Reports
-
2/1/2016 (reviewed: 10/17/2017)
Primary Care Guidelines
-
11/9/2015
Archive Resources: 11
Charts, Tables & Posters
-
9/4/2015
Reports
-
8/27/2015
Coinfection Guidelines (Hep, TB, STIs)
-
6/5/2015
Webinar Recordings
-
6/4/2015 (reviewed: 5/8/2019)
-
4/30/2015 (reviewed: 5/8/2019)
Slide Sets
-
5/19/2015
-
6/1/2014
-
1/15/2014
Videos
-
4/1/2015 (reviewed: 5/8/2019)
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
12/11/2014
-
1/28/2011
Articles: 6
-
Long-acting Injectable PrEP: Cabotegravir
A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir...
-
AETCs at the 2018 Ryan White Conference
The AETC Program was well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center exhibited an array of AETC Program developed resources and promotional items.
TitleSession IDTypePresenters/ PanelistsDate/time... -
U=U in PARTNER2 Study of MSM
PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).
PARTNER1 evaluated HIV transmission risk in a European...
-
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...
-
PrEP: Bone Density Improves after Stopping TDF/FTC
Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD). In both HIV-infected patients treated with TDF-containing ARV regimens, and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender women...
-
Tissue Levels of TAF: Too Low for PrEP?
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral...